With PARP inhibitors, the therapeutic landscape for metastatic castration-resistant prostate cancer (mCRPC) has been expanded by a new substance class since November 2020. Currently, the indication for this innovative therapy requires the presence of a mutation in one of the BRCA1/2 genes and prior hormonal therapy. This short review explains the molecular background and summarizes current clinical trials on PARP inhibition-also in combination with other therapy strategies. In view of positive data from the cited studies and the relatively high proportion of patients with "actionable" mutations, the personalized therapy concept of BRCA1/2 mutation-dependent PARP inhibition for mCRPC is now reflected in various guidelines including S3 guidelines.
Keyphrases
- prostate cancer
- dna damage
- clinical trial
- dna repair
- squamous cell carcinoma
- small cell lung cancer
- gene expression
- stem cells
- clinical practice
- adipose tissue
- oxidative stress
- dna methylation
- study protocol
- radical prostatectomy
- artificial intelligence
- deep learning
- polycystic ovary syndrome
- data analysis
- structural basis